ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 067

Clinical and Demographic Characteristics of Children with Anti-NMDAR Encephalitis

Yike Jiang, Alexander Sandweiss, Timothy Erickson, Eyal Muscal and Kristy Murray, Baylor College of Medicine, Houston, TX

Meeting: 2023 Pediatric Rheumatology Symposium

Keywords: Autoantibody(ies), Brain, neurology, Neuropsychiatry

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print
Session Information

Date: Thursday, March 30, 2023

Title: Posters: Clinical and Therapeutic I

Session Type: Poster Session A

Session Time: 6:00PM-7:00PM

Background/Purpose: The discovery of anti-N-methyl-d-aspartate receptor (NMDAR) encephalitis heralded a new class of neuropsychiatric illnesses mediated by autoantibodies, known collectively as autoimmune encephalitis. The clinical characteristics and potential triggers in pediatric cases of anti-NMDAR encephalitis are not well understood. In North America, diagnosis and immunomodulation of children with anti-NMDAR encephalitis are often undertaken by multi-disciplinary teams that include rheumatologists. Our objective is to characterize presentations and potential etiologies of childhood-onset anti-NMDAR encephalitis at a large tertiary urban center that covers a multi-state catchment area.

Methods: After IRB approval, we retrospectively reviewed the initial presentation of patients with anti-NMDAR encephalitis at Texas Children’s Hospital between 2009 and 2021.

Results: Our cohort included 76 children who were predominantly female (49/86, 64%) and Hispanic (50/76, 66%). The mean age of onset was 9.5 5.6 years old with a bimodal distribution. This was a larger number than presented annually with neuropsychiatric SLE during the study period (6 vs 2 per year). All children with anti-NMDAR encephalitis had behavioral/cognitive symptoms, 60 (79%) had seizures, 55 (73%) had speech abnormalities, 51 (67%) had movement disorders, and 46 (61%) had memory deficits. Regarding potential etiologies, 4 (5%) had ovarian teratoma (mean age 12.5 1.5 years), and 9 (12%) had a recent history of herpes simplex virus (HSV) encephalitis (mean age 3.7 1.4 years). The remaining 63 (83%) patients had no known causative trigger (mean age 10.1 0.7 years).

Conclusion: In a large single-center pediatric cohort of anti-NMDAR encephalitis, most cases were unrelated to HSV encephalitis or ovarian teratomas. Age of onset had a bimodal distribution representing pre-pubertal and post-pubertal. Female and Hispanic children were disproportionally affected compared to the general inpatient population.


Disclosures: Y. Jiang: None; A. Sandweiss: None; T. Erickson: None; E. Muscal: sobi, 1; K. Murray: None.

To cite this abstract in AMA style:

Jiang Y, Sandweiss A, Erickson T, Muscal E, Murray K. Clinical and Demographic Characteristics of Children with Anti-NMDAR Encephalitis [abstract]. Arthritis Rheumatol. 2023; 75 (suppl 4). https://acrabstracts.org/abstract/clinical-and-demographic-characteristics-of-children-with-anti-nmdar-encephalitis/. Accessed .
  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to 2023 Pediatric Rheumatology Symposium

ACR Meeting Abstracts - https://acrabstracts.org/abstract/clinical-and-demographic-characteristics-of-children-with-anti-nmdar-encephalitis/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology